Category Archives: Biotechnology

Under the agreement, Prague-based SOTIO Biotech AS will pay up to US$325.5m biobucks to use Biocytogens RenLite antibody discovery platform to design bispecific antibody drug conjugates (ADC) that home in on selected different cancer targets. The amount of the upfront payment was not specified. Biocytogen will be eligible to receive single-digit royalties on net sales on a product-by-product basis. SOTIO will be responsible for preclinical and clinical development, manufacturing, and commercialisation of the ADC products.

The contract also grants SOTIO the option to license multiple fully human bispecific antibodies generated with Biocytogens proprietary RenLite platform, which SOTIO will use to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumours. The agreement also includes an option for SOTIO to leverage Biocytogens proprietary ADC platform. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice (RenMab/RenLite/RenNano/RenTCR-mimic) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice licensing projects have been established around the globe

This agreement with Biocytogen complements our existing collaborations with Synaffix, LegoChem, and NBE-Therapeutics, providing SOTIO with access to fully human antibodies from Biocytogens state-of-the-art in vivo discovery platform, said Martin Steegmaier, CEO of SOTIO. With the first targets for a bispecific program already selected, we are well-positioned to expand our ADC pipeline and the therapeutic possibilities for patients with solid tumours.

The eight RenMice platforms can be used to discover fully human antibodies with high affinity, low immunogenicity, and favourable developability.

Currently, the SOTIO pipeline includes three clinical-stage programs: SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumours; and SOT201, a next-generation PD-1-targeting immunocytokine. SOTIO is a member of the PPF Grouphttps://european-biotechnology.com/latest-news/pff-group-nv-acquires-stake-in-autolus-therapeutics/.

The rest is here:
SOTIO partners with Biocytogen to expand ADC pipeline - European Biotechnology News

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB Get Free Report)s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $59.28 and traded as high as $65.21. ProShares Ultra Nasdaq Biotechnology shares last traded at $65.21, with a volume of 17,865 shares changing hands.

The stock has a 50 day simple moving average of $59.28 and a 200 day simple moving average of $57.27.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 3rd. Shareholders of record on Wednesday, June 26th were paid a $0.2648 dividend. This represents a $1.06 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date of this dividend was Wednesday, June 26th. This is a boost from ProShares Ultra Nasdaq Biotechnologys previous quarterly dividend of $0.04.

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each days returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Continued here:
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above Fifty Day Moving Average of $59.28 - Defense World

WESTFORD, Mass., July 18, 2024 /PRNewswire/ -- According to SkyQuest, the global Biotechnology Marketsize was valued at USD 1.21 Trillion in 2022 and is poised to grow from USD 1.38 Trillion in 2023 to USD 3.90 Trillion by 2031, growing at a CAGR of 13.9% during the forecast period (2024-2031).

Biotechnology is a diversified, innovative industry that uses organisms, biological systems, or their products to modify or develop processes and by-products to produce health-related products and treatments.

Biotechnology and related products are required to meet established regulatory guidelines and standards. The major federal agencies in the US responsible for administering the required standards are the Animal and Plant Health Inspection Service (APHIS), US. The Coordinated Framework for the Regulation of Biotechnology outlines a government framework for evaluating products developed using modern biotechnology. This provision is based on existing laws developed to protect public health and the environment.

Download a detailed overview:

https://www.skyquestt.com/sample-request/biotechnology-market

Biotechnology Market Overview:

Report Coverage

Details

Market Revenue in 2023

USD 1.38 Trillion

Estimated Value by 2031

USD 3.90 Trillion

Growth Rate

Poised to grow at a CAGR of 13.9%

Forecast Period

20242031

Forecast Units

Value (USD Trillion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Type, Product, Technology, Application and Region

Geographies Covered

North America, Europe, Asia Pacific, Middle East & Africa, Latin America

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Growth in Nanobiotechnology

Key Market Drivers

Growing Research and Development of Tissue Culture and Cell Engineering

Segments covered in Biotechnology Market are as follows:

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/biotechnology-market

DNA Sequencing Holds a Dominant Position in the Biotechnology Market Owing to the Rising Adoption of Advanced Techniques

DNA sequencing occupies a dominant position in the biotechnology market, accounting for about 17.43% by 2023. This growth is due to two main factors: cheaper sequencing costs and the adoption of advanced techniques and government funding also plays an important role. A grant like the one awarded by the NIH (National Institutes of Health) that may be $10.7 million by May 2021, directed toward understanding the genetics of Alzheimer's disease, is an example of this kind of funding. Such funding fuels research and it opens new applications for DNA sequencing, ideal for various diseases.

The nanobiotechnology segment is poised to surge from 2024 to 2031. Two main factors fuel this growth: more nanomedicine approvals and remarkable growth in the sector. In addition, nanoparticles for diagnosis are revolutionizing disease diagnosis, allowing for comparative diagnosis and personalized medicine simultaneously. Tissue technology and regenerative medicine is growing due to government and private investments, high healthcare spending, and the rise of established and new players.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/biotechnology-market

Healthcare Industry Led the Market Owing to the Enhance Revenue Generation

The healthcare industry led the market and is expected to register a compound annual growth rate (CAGR) of 13.9% throughout the forecast period. Healthcare biotechnology has proven its importance, emerging as the biggest revenue generator by 2020. Biotechnology innovation has given birth to new sectors of the economy, driven largely by small start-ups and interagency collaboration as they are also being used for further treatments to improve the sector. For example, in April 2020, Amgen and Adaptive Biotechnologies collaborated to identify and develop anti-SARS-CoV-2 vaccines using Adaptive's proprietary immunotherapy platform to find antibodies that neutralize viruses This agreement is expected this will significantly increase revenue in this sector.

The food and agriculture sector ranks second in the market. The tools used in agriculture have evolved rapidly, including micropropagation, tissue culture, molecular breeding, marker-assisted selection, genetic engineering, genetically modified (GM) crops, molecular diagnostic technologies, and new genetics providing a comprehensive understanding of plant biology. Moreover, the global adoption of GM crops is expected to boost the segments. GM crops, especially herbicide-resistant and pest-resistant seeds, have become increasingly popular, boosting the agricultural industry.

Biotechnology Market: Shaping the Future of Innovation

The market is at the forefront of scientific and technological innovation, poised to deliver transformative solutions to some of the world's most pressing challenges. Focusing on areas such as healthcare, agriculture and environmental sustainability, biotechnology is driving progress through cutting-edge research and development.

Advances in genetic engineering, bioinformatics and bioprocessing technologies are fueling the growth of this market. Specialty areas such as personalized medicine, gene therapy and sustainable agricultural practices can benefit from these innovations, delivering results and efficiency.

Strategic dialogue, investment in R&D and a favorable regulatory environment are going to drive the biotechnology market. Companies are constantly exploring new frontiers, from CRISPR-based gene editing to biotechnology, to unlock and address new possibilities.

Related Reports:

Biotechnology & Pharmaceutical Services Outsourcing Market

Plant Biotechnology Services Market

Marine Biotechnology Market

Genomics Market

Digital Health Market

About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Contact:Mr. Jagraj Singh SkyQuest Technology 1 Apache Way, Westford, Massachusetts 01886 USA (+1) 351-333-4748 Email: [emailprotected] Visit Our Website:https://www.skyquestt.com/

Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg

SOURCE SkyQuest Technology

Read this article:
Biotechnology Market: Surging Investments and Infrastructure Development Propel 13.9% CAGR by 2031| SkyQuest Technology - PR Newswire

International Biotechnology (LON:IBT Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 649.16 ($8.42) and traded as high as GBX 716 ($9.29). International Biotechnology shares last traded at GBX 698 ($9.05), with a volume of 70,982 shares trading hands.

The company has a current ratio of 0.27, a quick ratio of 0.32 and a debt-to-equity ratio of 8.19. The stock has a market capitalization of 273.20 million, a P/E ratio of 664.76 and a beta of 0.18. The stocks 50 day simple moving average is GBX 648.69 and its 200 day simple moving average is GBX 649.16.

The business also recently disclosed a dividend, which will be paid on Friday, August 23rd. Shareholders of record on Thursday, July 25th will be paid a dividend of GBX 14.50 ($0.19) per share. This represents a yield of 2.28%. This is an increase from International Biotechnologys previous dividend of $13.90. The ex-dividend date of this dividend is Thursday, July 25th. International Biotechnologys dividend payout ratio is 2,666.67%.

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments.

Receive News & Ratings for International Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read the rest here:
International Biotechnology (LON:IBT) Stock Price Passes Above 200 Day Moving Average of $649.16 - American Banking and Market News

Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.

As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics AG'simmuno-oncology spin-out. Apeiron shareholders are entitled to additional consideration based on future commercial and regulatory events and to up to US$28m ifdinutuximab beta(QarzibaTM) royalties exceed certain predetermined thresholds by either 2030 or 2034 respectively. The monoclonal antibody that specifically homes in at the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells is used as a second-line treatment for children with high-riskneuroblastoma The acquisition is expected to close in July 2024. The invIOs proceeds will help the company to finance R&D of three early-stage immuno-oncology programmes.Apeiron is entitled to royalties and milestone payments on these assets. This transaction is also expected to close in July 2024.

Apeiron Biologics received EMA marketing autorisation for APN311 (dinutuximab beta in 2017 for the treatment of high-risk neuroblastoma in infants aged twelve months and above. Peter Llewellyn-Davies, CEO ofApeiron Biologics and co-founder of the Austrian Biotech Association, said: "This is a historic moment for Apeiron and its shareholders. We are excited that Ligand has recognized the long-term potential of Qarziba. The sale of Apeiron is an encouraging signal for the entire Austrian biotechnology industry, it underlines the great potential of Austrias research-driven biotechnology companies."

See more here:
Ligand Pharma to acquire Apeiron Biologics - European Biotechnology News

Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.

According to the agreement, GW Vitek will represent EuroscreenFasts discovery and lead optimisation capabilities in the Republic of Korea. While EuroscreenFast has had some presence in East-Asia, this partnership will enable significant expansion of its commercial reach into the Korean market. Through the leveraging of GW Viteks extensive distribution network and market expertise, EuroscreenFast aims to provide its cutting-edge GPCR cell-based assay services and a robust deorphanisation offering to a broader range of clients.

This partnership with EuroscreenFast further strengthens GW Viteks position as Koreas go-to provider of biotherapeutic research solutions for both biologics and chemical therapeutics, said Jaewon Yang, CEO at GW Vitek. We are excited to offer EuroscreenFasts advanced GPCR screening technologies to our clients, which is a new area of expansion for our already broad catalogue of instruments and wet-lab services. the CRO EuroscreenFast has been a pioneer in GPCR science for more than 30 years, offering over 1,000 functional assays across more than 530 GPCR and other targets. EuroscreenFast also boasts a deorphanisation track record with the identification of 17 natural receptor-ligand pairs. Custom assay development and specialised tools to bridge the gap between in vitro and in vivo data are even more reasons why therapeutic developers worldwide know that EuroscreenFast is the unrivalled GPCR development partner. EuroscreenFast is a business unit of Epics Therapeutics SA.

See the original post here:
EuroscreenFast and GW Vitek announce distribution partnership in Korea - European Biotechnology News

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024.

The companys management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the Investors section of the company website at: http://www.nautilus.bio.

About Nautilus Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit http://www.nautilus.bio.

Media Contact press@nautilus.bio

Investor Contact investorrelations@nautilus.bio

Read more:
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024 - GlobeNewswire

Syensqo and Allozymes, a Singapore-based enzyme engineering start-up, have signed a Memorandum of Understanding to leverage both companies' strengths in biotechnology to develop advanced biosolutions for the personal care (especially skin care) and home care markets.

See related: Syensqo Invests in Green Solvents Producer Startup Bioeutectics

According to Syensqo, Allozymes brings to the partnership a unique ultra-high throughput microfluidics platform for the engineering of enzymes and microbes. This reportedly will enable the rapid and cost-effective development of bio-manufactured ingredients and bioprocesses, "setting a new standard for innovation and sustainability in the industry."

Syensqo will apply its application and market access expertise, including strategies torapidly extend biotech ingredient solutions into beauty. The recent acquisition of South Korean ceramides specialist JinYoung Bio demonstrates this strength.

By combining Allozymes technological capabilities with Syensqo's application and market access expertise, we are poised to create groundbreaking solutions that will not only benefit the home and personal care market, but also contribute to a more sustainable future, said Thomas Canova, head of renewable materials and biotechnology growth platform at Syensqo.

Our partnership with Syensqo embodies our mutual commitment to a sustainable future, leveraging biotechnology to enable cleaner, greener processes, ensuring our actions today contribute to a healthier planet for future generations, ..." added Peyman Salehian, Ph.D., CEO and co-founder at Allozymes.

See also: Syensqo's Latest Ingredients in Skin and hair Care at in-cosmetics Global

More here:
Syensqo, Allozymes to Jointly Pioneer Enzyme-powered Personal Care, Skin Care Biosolutions - Cosmetics & Toiletries

Published 15 hours ago

Submitted by Illumina

Illumina ranks 5th overall and is the top-ranking company in the U.S. and the biotechnology industry in TIMEs World's Most Sustainable Companies 2024 list.

The list ranks the top 500 companies out of more than 3,000 reviewed, based on various environmental metrics, including energy intensity, emissions, employee turnover, and work safety.

TIMEs announcement highlighted Illuminas work to reduce packaging by 90% with the NovaSeqTM X Series, showcasing that manufacturing companies can also be sustainability champions. Illuminas inclusion demonstrates the work being done by our employees to make our operations, supply chain, and products more sustainable, including:

At Illumina, we are driven by the power of genomics to positively impact the world and shape a more sustainable and equitable future for all. We know that improving human health is tied to creating a healthier planet. By making bold environmental commitments, and helping our customers achieve their sustainability goals, we are bringing our mission to life.

Learn more about our commitment and progress to integrating sustainability into our business here.

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

More from Illumina

Follow this link:
Illumina Ranks 5th Overall in TIMEs Worlds Most Sustainable Companies 2024 List - CSRwire.com

The delegation, comprised of the vice minister and representatives from four biotechnology firms, aimed to explore business opportunities, foster collaborations with Korean counterparts, and promote the Biotechnology Valley. This bioscience development and production infrastructure is located near Istanbul, a city that bridges Europe and Asia.

During the opening event, Vice Minister Dnmez expressed his hopes for stronger ties with Korea in the biotechnology sector.

"We would like to strengthen our relations with The Republic of Korea in the field of biotechnology and to establish concrete collaborations between our companies," he said. "We hope that this exhibition will be an important opportunity in this respect."

Caglar Kaharaman, a regional operations manager at Bio SB, a Turkish biotechnology firm specializing in the production and distribution of antibodies and detection systems for immunohistochemistry, highlighted the potential of Istanbul's Biotechnology Valley as a production hub for foreign companies.

"There is no other infrastructure that has better geographical advantages than our Biotechnology Valley," Kaharaman told Aju Press. He explained that setting up a base at the technology complex, which can host more than 400 manufacturers, allows firms to target markets in Europe, Asia, the Middle East, and beyond.

"We hope to collaborate with more Korean partners to create synergy, especially in the fields of healthcare and cosmetics. I strongly believe that the Biotechnology Valley will provide great business opportunities for Korean companies looking to expand into new markets," Kaharaman added.

Park Sae-jin swatchsjp@ajunews.com

More:
Turkish delegation seeks business partnership opportunities at biotech conference in Seoul - Aju Press